|
2
|
Gaillard N, Sharma A, Abbaali I, Liu T, Shilliday F, Cook AD, Ehrhard V, Bangera M, Roberts AJ, Moores CA, Morrissette N, Steinmetz MO. Inhibiting parasite proliferation using a rationally designed anti-tubulin agent. EMBO Mol Med 2021; 13:e13818. [PMID: 34661376 PMCID: PMC8573600 DOI: 10.15252/emmm.202013818] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 09/17/2021] [Accepted: 09/29/2021] [Indexed: 11/09/2022] Open
Abstract
Infectious diseases caused by apicomplexan parasites remain a global public health threat. The presence of multiple ligand-binding sites in tubulin makes this protein an attractive target for anti-parasite drug discovery. However, despite remarkable successes as anti-cancer agents, the rational development of protozoan parasite-specific tubulin drugs has been hindered by a lack of structural and biochemical information on protozoan tubulins. Here, we present atomic structures for a protozoan tubulin and microtubule and delineate the architectures of apicomplexan tubulin drug-binding sites. Based on this information, we rationally designed the parasite-specific tubulin inhibitor parabulin and show that it inhibits growth of parasites while displaying no effects on human cells. Our work presents for the first time the rational design of a species-specific tubulin drug providing a framework to exploit structural differences between human and protozoa tubulin variants enabling the development of much-needed, novel parasite inhibitors.
Collapse
Affiliation(s)
- Natacha Gaillard
- Laboratory of Biomolecular ResearchDivision of Biology and ChemistryPaul Scherrer InstitutVilligenSwitzerland
| | - Ashwani Sharma
- Laboratory of Biomolecular ResearchDivision of Biology and ChemistryPaul Scherrer InstitutVilligenSwitzerland
| | - Izra Abbaali
- Department of Molecular Biology and BiochemistryUniversity of CaliforniaIrvineCaliforniaUSA
| | - Tianyang Liu
- Institute of Structural and Molecular BiologyBirkbeck, University of LondonLondonUK
| | - Fiona Shilliday
- Institute of Structural and Molecular BiologyBirkbeck, University of LondonLondonUK
| | - Alexander D Cook
- Institute of Structural and Molecular BiologyBirkbeck, University of LondonLondonUK
| | - Valentin Ehrhard
- Laboratory of Biomolecular ResearchDivision of Biology and ChemistryPaul Scherrer InstitutVilligenSwitzerland
| | - Mamata Bangera
- Institute of Structural and Molecular BiologyBirkbeck, University of LondonLondonUK
| | - Anthony J Roberts
- Institute of Structural and Molecular BiologyBirkbeck, University of LondonLondonUK
| | - Carolyn A Moores
- Institute of Structural and Molecular BiologyBirkbeck, University of LondonLondonUK
| | - Naomi Morrissette
- Department of Molecular Biology and BiochemistryUniversity of CaliforniaIrvineCaliforniaUSA
| | - Michel O Steinmetz
- Laboratory of Biomolecular ResearchDivision of Biology and ChemistryPaul Scherrer InstitutVilligenSwitzerland
- Biozentrum University of BaselBaselSwitzerland
| |
Collapse
|
|
3
|
Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin. Future Med Chem 2021; 13:839-858. [PMID: 33821673 DOI: 10.4155/fmc-2020-0376] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Microtubules have been a concerning target of cancer chemotherapeutics for decades, and several tubulin-targeted agents, such as paclitaxel, vincristine and vinorelbine, have been approved. The colchicine binding site is one of the primary targets on microtubules and possesses advantages compared with other tubulin-targeted agents, such as inhibitors of tumor vessels and overcoming P-glycoprotein overexpression-mediated multidrug resistance. This study reviews and summarizes colchicine binding site inhibitors reported in recent years with structural studies via the crystal structures of complexes or computer simulations to discover new lead compounds. We are attempting to resolve the challenge of colchicine site agent research.
Collapse
|
|
4
|
Han HJ, Park C, Hwang J, N.R. T, Kim SO, Han J, Woo M, B S, Ryoo IJ, Lee KH, Cha-Molstad H, Kwon YT, Kim BY, Soung NK. CPPF, A Novel Microtubule Targeting Anticancer Agent, Inhibits the Growth of a Wide Variety of Cancers. Int J Mol Sci 2020; 21:ijms21134800. [PMID: 32645923 PMCID: PMC7370279 DOI: 10.3390/ijms21134800] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 07/04/2020] [Accepted: 07/06/2020] [Indexed: 12/24/2022] Open
Abstract
In the past, several microtubule targeting agents (MTAs) have been developed into successful anticancer drugs. However, the usage of these drugs has been limited by the acquisition of drug resistance in many cancers. Therefore, there is a constant demand for the development of new therapeutic drugs. Here we report the discovery of 5-5 (3-cchlorophenyl)-N-(3-pyridinyl)-2-furamide (CPPF), a novel microtubule targeting anticancer agent. Using both 2D and 3D culture systems, we showed that CPPF was able to suppress the proliferation of diverse cancer cell lines. In addition, CPPF was able to inhibit the growth of multidrug-resistant cell lines that are resistant to other MTAs, such as paclitaxel and colchicine. Our results showed that CPPF inhibited growth by depolymerizing microtubules leading to mitotic arrest and apoptosis. We also confirmed CPPF anticancer effects in vivo using both a mouse xenograft and a two-step skin cancer mouse model. Using established zebrafish models, we showed that CPPF has low toxicity in vivo. Overall, our study proves that CPPF has the potential to become a successful anticancer chemotherapeutic drug.
Collapse
Affiliation(s)
- Ho Jin Han
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
- Department of Biomolecular Science, University of Science and Technology, Daejeon 34113, Korea
| | - Chanmi Park
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
| | - Joonsung Hwang
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
| | - Thimmegowda N.R.
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
| | - Sun-Ok Kim
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
| | - Junyeol Han
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
- Department of Biomolecular Science, University of Science and Technology, Daejeon 34113, Korea
| | - Minsik Woo
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
- College of Pharmacy and Medical Research Center, Chungbuk National University, Osong, Cheongju 28160, Korea
| | - Shwetha B
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
| | - In-Ja Ryoo
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
| | - Kyung Ho Lee
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
| | - Hyunjoo Cha-Molstad
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
| | - Yong Tae Kwon
- Protein Metabolism Medical Research Center and Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Korea
- Correspondence: (Y.T.K.); (B.Y.K.); (N.-K.S.); Tel.: +82-2-740-8547 (Y.T.K.); +82-43-240-6163 (B.Y.K.); +82-43-240-6165 (N.-K.S.); Fax: +82-2-3673-2167 (Y.T.K.); +82-43-240-6259 (B.Y.K.); +82-43-240-6259 (N.-K.S.)
| | - Bo Yeon Kim
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
- Department of Biomolecular Science, University of Science and Technology, Daejeon 34113, Korea
- Correspondence: (Y.T.K.); (B.Y.K.); (N.-K.S.); Tel.: +82-2-740-8547 (Y.T.K.); +82-43-240-6163 (B.Y.K.); +82-43-240-6165 (N.-K.S.); Fax: +82-2-3673-2167 (Y.T.K.); +82-43-240-6259 (B.Y.K.); +82-43-240-6259 (N.-K.S.)
| | - Nak-Kyun Soung
- Anticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Cheongju 28116, Korea; (H.J.H.); (C.P.); (J.H.); (T.N.R.); (S.-O.K.); (J.H.); (M.W.); (S.B.); (I.-J.R.); (K.H.L.); (H.C.-M.)
- Correspondence: (Y.T.K.); (B.Y.K.); (N.-K.S.); Tel.: +82-2-740-8547 (Y.T.K.); +82-43-240-6163 (B.Y.K.); +82-43-240-6165 (N.-K.S.); Fax: +82-2-3673-2167 (Y.T.K.); +82-43-240-6259 (B.Y.K.); +82-43-240-6259 (N.-K.S.)
| |
Collapse
|
|
6
|
Korcz M, Sączewski F, Bednarski PJ, Kornicka A. Synthesis, Structure, Chemical Stability, and In Vitro Cytotoxic Properties of Novel Quinoline-3-Carbaldehyde Hydrazones Bearing a 1,2,4-Triazole or Benzotriazole Moiety. Molecules 2018; 23:E1497. [PMID: 29925826 PMCID: PMC6100353 DOI: 10.3390/molecules23061497] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2018] [Revised: 06/15/2018] [Accepted: 06/16/2018] [Indexed: 11/23/2022] Open
Abstract
A small library of novel quinoline-3-carbaldehyde hydrazones (Series 1), acylhydrazones (Series 2), and arylsulfonylhydrazones (Series 3) bearing either a 1,2,4-triazole or benzotriazole ring at position 2 was prepared, characterized by elemental analyses and IR, NMR, and MS spectra, and then subjected to in vitro cytotoxicity studies on three human tumor cell lines: DAN-G, LCLC-103H, and SISO. In general, compounds 4, 6, and 8 substituted with a 1,2,4-triazole ring proved to be inactive, whereas the benzotriazole-containing quinolines 5, 7, and 9 elicited pronounced cancer cell growth inhibitory effects with IC50 values in the range of 1.23⁻7.39 µM. The most potent 2-(1H-benzotriazol-1-yl)-3-[2-(pyridin-2-yl)hydrazonomethyl]quinoline (5e) showed a cytostatic effect on the cancer cell lines, whereas N′-[(2-(1H-benzotriazol-1-yl)quinolin-3-yl)methylene]-benzohydrazide (7a) and N′-[(2-1H-benzotriazol-1-yl)quinolin-3-yl)methylene]-naphthalene-2-sulfonohydrazide (9h) exhibited selective activity against the pancreas cancer DAN-G and cervical cancer SISO cell lines. Based on the determined IC50 values, the compound 5e seems to be leading compound for further development as anticancer agent.
Collapse
Affiliation(s)
- Martyna Korcz
- Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland.
| | - Franciszek Sączewski
- Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland.
| | - Patrick J Bednarski
- Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, F.-L. Jahn Strasse 17, D-17489 Greifswald, Germany.
| | - Anita Kornicka
- Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland.
| |
Collapse
|
|
7
|
Design and Antiproliferative Evaluation of Novel Sulfanilamide Derivatives as Potential Tubulin Polymerization Inhibitors. Molecules 2017; 22:molecules22091470. [PMID: 28872607 PMCID: PMC6151726 DOI: 10.3390/molecules22091470] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Revised: 08/21/2017] [Accepted: 08/31/2017] [Indexed: 01/28/2023] Open
Abstract
A series of sulfanilamide-1,2,3-triazole hybrids were designed by a molecular hybridization strategy and evaluated for antiproliferative activity against three selected cancer cell lines (MGC-803, MCF-7 and PC-3). The detailed structure-activity relationships for these sulfanilamide-1,2,3-triazole hybrids were investigated. All these sulfanilamide-1,2,3-triazole hybrids exhibited moderate to potent activity against all cell lines. In particular 4-methyl-N-((1-(3-phenoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)benzenesulfonamide (11f) showed the most potent inhibitory effect against PC-3 cells, with an IC50 value of 4.08 μM. Furthermore, the tubulin polymerization inhibitory activity in vitro of compound 11f was 2.41 μM. These sulfanilamide hybrids might serve as bioactive fragments for developing more potent antiproliferative agents.
Collapse
|